Equities & sectorsJefferies Standout
What’s Driving Healthcare Dealmaking Right Now?
United States ChinaArtificial intelligence
Our summary
Healthcare dealmaking is entering an early expansion phase as mature biotech science, strategic specialty-pharma combinations and rising Chinese competition bring capital markets closer to the sector’s scientific progress.
- Deal value in the first half of 2026 already matched the total for 2025, as large-cap pharmaceutical companies pursued biotech assets that reached clinical maturity after COVID-era funding.
- U.S. specialty-pharma M&A is returning through strategic transactions, including Sun Pharmaceuticals’ $11.75 billion acquisition of Organon, MannKind’s 2025 purchase of scPharmaceuticals and the Indivior-Supernus combination.
- AI is producing measurable gains in pharma services, manufacturing and commercialization. At a Jefferies-hosted CDMO summit, a CEO described an AI system identifying an overheating piston before failure and avoiding days of lost production.
- Chinese-originated assets represented $92 billion of licensing deals in the first six months of 2026, while antibody-drug-conjugate development has created competition from roughly 20 Chinese biotechs for some Western opportunities.
- Roughly two-thirds of venture rounds in the first half of 2026 went to companies with drugs already in human clinical testing, while nine to twelve months between deal announcement and completion means much of the M&A capital has yet to return to the sector.
Takeaway: Investors should expect further strategic healthcare M&A, stronger biotech IPO activity and broader capital distribution as acquired-company proceeds recycle into the sector, with Chinese scientific competition becoming a central constraint for Western biotechs.
Published by Jefferies. Summary by HF Best Ideas.